Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-08-18

Clinical Trial Update: Combining Lesinurad With Allopurinol in Inadequate Responders [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated adding lesinurad to allopurinol in gout patients who did not respond adequately, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zurampic (lesinurad)
  • Zyloprim (allopurinol)

Snippet

Sponsor: Ardea Biosciences, Inc. | Conditions: Gout | Phase 3 | Status: COMPLETED | Results posted: 2016-08-18